# SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC

> **NCT07489703** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** SHR-A1811 plus AK112

## Key facts

- **NCT ID:** NCT07489703
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07489703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07489703, "SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07489703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*